Hibercell, Inc.
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
3
Ending by 2030
Jun 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 6, 2026The maintenance fee for Aminopyridine Derivatives as Phosphatidylinositol Phosphate Kinase Inhibitors (US 11,667,651) comes due Dec 6, 2026. Unpaid by Jun 7, 2027, it lapses early.
- 1 fee due May 14, 2027The maintenance fee for Beta Glucan Immunopharmacodynamics (US 11,815,435) comes due May 14, 2027. Unpaid by Nov 15, 2027, it lapses early.
- 2 fees due Sep 5 to 10, 2027 · next Sep 5
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
- Nov 17 US 12,799,117 Perk Inhibiting Pyrrolopyrimidine Compounds
- 2 terms have ended since Aug 23, 2026
- Oct 30 US 10,114,027 Beta-Glucan Assay Methods · lapsed on the fee record
- Oct 9 US 10,092,657 Opsonized Beta-Glucan Preparations and Methods · lapsed on the fee record
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,272,101 | Glucan Preparations In force · High confidence | In force | High confidence | |
| US 7,981,447 | Particulate-Soluble Glucan Preparation In force · High confidence | In force | High confidence | |
| US 9,610,303 | Glucan preparations In force · High confidence | In force | High confidence | |
| US 9,694,070 | Compositions Including Beta-Glucans and Methods of Use In force · High confidence | In force | High confidence | |
| US 9,943,607 | Beta-Glucan Compounds, Compositions, and Methods In force · High confidence | In force | High confidence | |
| US 10,166,289 | Compositions Including Beta-Glucans and Method of Use In force · Medium confidence | In force | Medium confidence | |
| US 12,390,526 | Methods for Identifying Beta-Glucan Binding to Immune Cells In force · High confidence | In force | High confidence | |
| US 11,229,701 | Methods for Identifying Beta-Glucan Binding to Immune Cells In force · High confidence | In force | High confidence | |
| US 9,885,726 | Beta-Glucan Assay Methods In force · High confidence | In force | High confidence | |
| US 10,092,646 | Compositions and Methods for Beta-Glucan Immunotherapy In force · High confidence | In force | High confidence |
Also on record, not counted in the 22: 2 patents in force now held by others · 2 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
9 pending · 6 abandoned · 1 no status recorded
Showing 1 to 10 of 16, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.
| Application | Title | Filed | Status |
|---|---|---|---|
| 18/893,406 | Beta-Glucan Immunotherapies Affecting the Immune Microenvironment | Sep 23, 2024 | Pending |
| 18/668,665 | Beta-Glucan in Combination with Anti-Cancer Agents Affecting the Tumor Micrenvironment | May 20, 2024 | Pending |
| 18/666,898 | Beta-Glucan Methods and Compositions That Affect the Tumor Microenvironment | May 17, 2024 | Pending |
| 18/493,604 | Beta-Glucan in Combination with Anti-Cancer Agents Affecting the Tumor Microenvironment | Oct 24, 2023 | Abandoned |
| 18/470,273 | Sep 19, 2023 | No status recorded | |
| 18/869,103 | GCN2 Modulator for Treating Cancer | May 25, 2023 | Pending |
| 18/303,264 | Aminopyridine Derivatives as Phosphatidylinositol Phosphate Kinase Inhibitors | Apr 19, 2023 | Abandoned |
| 17/887,144 | Beta-Glucan Immunotherapies Affecting the Immune Microenvironment | Aug 12, 2022 | Abandoned |
| 18/262,493 | GCN2 Modulating Compounds and Uses Thereof | Jan 21, 2022 | Pending |
| 18/262,489 | GCN2 Modulating Compounds and Uses Thereof | Jan 21, 2022 | Pending |
10 of 16 applications shown.
Pro members see all 16 published applications.